OPK has been the topic of several other research reports. JPMorgan Chase & Co. set a $14.00 price target on Opko Health and gave the company a buy rating in a report on Tuesday, August 9th. Zacks Investment Research cut Opko Health from a hold rating to a sell rating in a report on Friday, July 1st. Deutsche Bank AG decreased their price target on Opko Health from $11.00 to $10.00 and set a hold rating on the stock in a report on Thursday, June 16th. Standpoint Research raised their price target on Opko Health from $16.00 to $18.00 and gave the company a buy rating in a report on Tuesday, June 21st. Finally, Oppenheimer Holdings Inc. reiterated a hold rating on shares of Opko Health in a report on Thursday, June 16th. Five equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of Buy and an average target price of $13.20.
Shares of Opko Health (NYSE:OPK) traded down 1.61% during trading on Monday, hitting $9.79. The stock had a trading volume of 584,268 shares. Opko Health has a 1-year low of $7.12 and a 1-year high of $11.85. The firm has a 50 day moving average of $10.06 and a 200 day moving average of $10.09. The company has a market capitalization of $5.39 billion and a price-to-earnings ratio of 40.96.
Opko Health (NYSE:OPK) last posted its quarterly earnings results on Monday, August 8th. The company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.05. The firm earned $357.10 million during the quarter, compared to the consensus estimate of $324.11 million. Opko Health’s revenue was up 742.2% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.09) EPS. Analysts expect that Opko Health will post ($0.05) EPS for the current fiscal year.
In other Opko Health news, CEO Phillip Md Et Al Frost purchased 10,000 shares of the company’s stock in a transaction dated Wednesday, July 27th. The shares were bought at an average price of $9.91 per share, with a total value of $99,100.00. Following the completion of the transaction, the chief executive officer now directly owns 3,068,951 shares in the company, valued at approximately $30,413,304.41. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Large investors have recently made changes to their positions in the stock. Williams Jones & Associates LLC raised its stake in shares of Opko Health by 352.0% in the second quarter. Williams Jones & Associates LLC now owns 11,300 shares of the company’s stock worth $106,000 after buying an additional 8,800 shares in the last quarter. IFP Advisors Inc raised its stake in shares of Opko Health by 72.5% in the second quarter. IFP Advisors Inc now owns 1,315,215 shares of the company’s stock worth $12,284,000 after buying an additional 552,645 shares in the last quarter. Public Employees Retirement System of Ohio raised its stake in shares of Opko Health by 11.9% in the second quarter. Public Employees Retirement System of Ohio now owns 113,894 shares of the company’s stock worth $1,064,000 after buying an additional 12,075 shares in the last quarter. Amalgamated Bank raised its stake in shares of Opko Health by 40.7% in the second quarter. Amalgamated Bank now owns 50,359 shares of the company’s stock worth $506,000 after buying an additional 14,559 shares in the last quarter. Finally, Family Management Corp raised its stake in shares of Opko Health by 41.3% in the second quarter. Family Management Corp now owns 30,670 shares of the company’s stock worth $286,000 after buying an additional 8,970 shares in the last quarter.
Opko Health Company Profile
OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.
Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.